A biotechnology company focused on developing and commercializing vaccines, with its primary marketed product being HEPLISAV-B, a hepatitis B vaccine for adults. The company also develops and licenses its CpG 1018 adjuvant technology, which is used to enhance immune responses in vaccines developed w...
5 members of Congress have disclosed 16 trades in Dynavax Technologies Holdings Corp (DVAX), a Healthcare company. The buy/sell breakdown shows 10 purchases versus 6 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2016-01-08 | JAMES B. RENACCI | buy | $1K – $15K |
| 2015-12-14 | JAMES B. RENACCI | buy | $1K – $15K |
| 2015-10-28 | JAMES B. RENACCI | buy | $1K – $15K |
| 2015-10-21 | JAMES B. RENACCI | buy | $1K – $15K |
| 2015-10-20 | JAMES B. RENACCI | buy | $1K – $15K |
| 2015-07-20 | JAMES B. RENACCI | buy | $1K – $15K |
| 2015-07-20 | JAMES B. RENACCI | buy | $1K – $15K |
| 2012-04-05 | JOHN K. DELANEY | sell | $1K – $15K |
| 2010-11-02 | SHELLEY BERKLEY | buy | -1,001.07 |
| 2010-10-02 | SHELLEY BERKLEY | sell | 334.39 |
| 2010-01-10 | SHELLEY BERKLEY | buy | -1,418.06 |
| 2009-07-08 | Lamar Smith | sell | $1K – $15K |
| 2009-05-08 | Lamar Smith | sell | $1K – $15K |
| 2008-03-09 | MICHAEL T. MCCAUL | sell | — |
| 2008-02-09 | MICHAEL T. MCCAUL | sell | — |
| 2001-08-08 | Lamar Smith | buy | $1,538.50 |